In fact, this pharmacological class improved glucose homeostasis and reduced body weight [13], but interestingly, large cardiovascular outcome trials showed that GLP-1 agonists were not only well tolerated, but also reduced the risk of cardiovascular and renal outcomes in T2DM patients [14]. Here, GCG is linked to type 2 diabetes mellitus.